$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417023801 Filed on May 02, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.310M	$1.490M	$1.340M
YoY Change	1.55%	71.26%	15.52%
% of Gross Profit
Research & Development	$534.6K	$709.9K	$440.0K
YoY Change	21.89%	83.78%	2.33%
% of Gross Profit
Depreciation & Amortization	$358.00	$357.00
YoY Change
% of Gross Profit
Operating Expenses	$1.841M	$2.204M	$1.780M
YoY Change	6.26%	75.67%	11.25%
Operating Profit	-$1.841M	-$2.204M
YoY Change	6.26%	75.67%
Interest Expense	$0.00	$26.82K	-$30.00K
YoY Change	-100.0%	-59.87%	-107.32%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.780M	-$1.870M	-$1.820M
YoY Change	0.56%	49.6%	65.45%
Income Tax
% Of Pretax Income
Net Earnings	-$1.776M	-$1.869M	-$1.820M
YoY Change	0.56%	49.19%	65.45%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$12.11K	-$13.31K	-$12.40K
COMMON SHARES
Basic Shares Outstanding	150.8M shares	138.6M shares	134.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.170M	$7.230M	$5.040M
YoY Change	7.3%	332.93%	27.27%
Cash & Equivalents	$6.169M	$7.230M	$5.036M
Short-Term Investments
Other Short-Term Assets	$150.0K	$350.0K	$110.0K
YoY Change	-6.25%	288.89%	175.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.320M	$7.576M	$5.144M
YoY Change	7.12%	330.58%	28.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.458K	$3.816K	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change
Total Long-Term Assets	$3.458K	$3.816K	$0.00
YoY Change		503.8%
TOTAL ASSETS
Total Short-Term Assets	$6.320M	$7.576M	$5.144M
Total Long-Term Assets	$3.458K	$3.816K	$0.00
Total Assets	$6.320M	$7.579M	$5.144M
YoY Change	7.12%	330.65%	28.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$210.0K	$208.6K	$374.9K
YoY Change	-57.14%	49.02%	61.76%
Accrued Expenses	$160.0K	$150.0K	$600.0K
YoY Change	-15.79%	-6.25%	140.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$900.0K
YoY Change		-100.0%	91.49%
Total Short-Term Liabilities	$370.3K	$362.8K	$1.879M
YoY Change	-45.54%	-9.31%	46.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$80.00K
YoY Change	-100.0%	-100.0%	-91.75%
Other Long-Term Liabilities	$2.570M	$2.630M	$30.00K
YoY Change	756.67%	874.07%	-85.71%
Total Long-Term Liabilities	$2.570M	$2.635M	$104.5K
YoY Change	100.78%	111.98%	-91.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$370.3K	$362.8K	$1.879M
Total Long-Term Liabilities	$2.570M	$2.635M	$104.5K
Total Liabilities	$2.940M	$2.997M	$1.983M
YoY Change	50.0%	82.56%	-19.47%
SHAREHOLDERS EQUITY
Retained Earnings		-$24.99M	-$21.71M
YoY Change		37.8%	38.11%
Common Stock		$29.57M	$24.88M
YoY Change		63.0%	44.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.380M	$4.582M	$3.161M
YoY Change
Total Liabilities & Shareholders Equity	$6.320M	$7.579M	$5.144M
YoY Change	7.12%	330.65%	28.51%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q3
OPERATING ACTIVITIES
Net Income	-$1.776M	-$1.869M	-$1.820M
YoY Change	0.56%	49.19%	65.45%
Depreciation, Depletion And Amortization	$358.00	$357.00
YoY Change
Cash From Operating Activities	-$980.0K	-$2.030M	-$1.090M
YoY Change	-26.32%	70.59%	-32.3%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-90.00K	5.480M	370.0K
YoY Change	-101.66%	13600.0%	-83.91%
NET CHANGE
Cash From Operating Activities	-980.0K	-2.030M	-1.090M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	-90.00K	5.480M	370.0K
Net Change In Cash	-1.070M	3.450M	-720.0K
YoY Change	-126.23%	-400.0%	-204.35%
FREE CASH FLOW
Cash From Operating Activities	-$980.0K	-$2.030M	-$1.090M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$980.0K	-$2.030M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	26230	USD
CY2017Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2634604	USD
CY2016Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	104485	USD
CY2017Q1	us-gaap	Liabilities Liabilities	2997378	USD
CY2016Q3	us-gaap	Liabilities Liabilities	1983265	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	147019	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	134432	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29420481	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	24741153	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21714590	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	4581978	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	3160995	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7579356	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5144260	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1878780	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	362774	USD
CY2016Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	299487	USD
CY2017Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	154140	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	208634	USD
CY2017Q1	us-gaap	Assets Assets	7579356	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2520847	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	0	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24985522	USD
CY2017Q1	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3816	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2017Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	3816	USD
CY2016Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1733946	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	800288	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1059206	USD
	us-gaap	Operating Expenses OperatingExpenses	2534234	USD
	us-gaap	Operating Expenses OperatingExpenses	3580053	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2534234	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3580053	USD
	us-gaap	Interest Expense InterestExpense	210569	USD
	us-gaap	Interest Expense InterestExpense	52385	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	192128	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	361506	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	124523	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	309121	USD
	arth	Gain On Exercise Of Warrants GainOnExerciseOfWarrants	142964	USD
	arth	Gain On Exercise Of Warrants GainOnExerciseOfWarrants	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2409711	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3270932	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	137893324	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	109069824	shares
CY2016Q1	us-gaap	Revenues Revenues	0	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	868433	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1494204	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	386285	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	709919	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	1254718	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	2204123	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1254718	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2204123	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	66823	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	26815	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	54982	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	361506	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1662	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	334691	USD
CY2016Q1	arth	Gain On Exercise Of Warrants GainOnExerciseOfWarrants	13503	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7230310	USD
CY2016Q3	us-gaap	Assets Assets	5144260	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	7575540	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	345230	USD
CY2016Q3	us-gaap	Cash Cash	5036476	USD
CY2017Q1	us-gaap	Cash Cash	7230310	USD
CY2016Q3	us-gaap	Interest Payable Current InterestPayableCurrent	304770	USD
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2016Q3	us-gaap	Notes Payable Current NotesPayableCurrent	899627	USD
CY2017Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2016Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	78255	USD
CY2017Q1	arth	Gain On Exercise Of Warrants GainOnExerciseOfWarrants	0	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-1253056	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-1869432	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	140513488	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	109524010	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	358330	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1013367	USD
	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	210569	USD
	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	22118	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	47200	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	237446	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-96146	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-247825	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-64101	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-157471	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2330851	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3408218	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	40000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5606345	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2290851	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2193834	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3960100	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5036476	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1669249	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	40000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	537659	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-192128	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-361506	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	536278	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-162000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-52500	USD
	us-gaap	Depreciation Depreciation	477	USD
	us-gaap	Depreciation Depreciation	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-331000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4293	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4293	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	4402	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	3925	USD
CY2017Q1	us-gaap	Depreciation Depreciation	357	USD
CY2016Q1	us-gaap	Depreciation Depreciation	0	USD
CY2013Q2	arth	Increase In Aggregate Number Of Shares IncreaseInAggregateNumberOfShares	3000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7657	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1944	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0103	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0240	pure
	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2515000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	240000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	150000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	10571654	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14504210	shares
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.38
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.63
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.35
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm	P0Y
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P5Y6M4D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y11D
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue	0	USD
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	3236700	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3876689	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.40
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.35
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.38
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11D
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4341816	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3876689	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1465861	shares
CY2015Q1	arth	Gain Loss On Warrant Derivative Modification GainLossOnWarrantDerivativeModification	624016	USD
CY2015Q2	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	3263753	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2800	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	USD
CY2016Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	977882	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	16600	USD
CY2015Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.20
CY2016Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	0	USD
CY2017Q1	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	354988	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	395012	USD
CY2016Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Arch Therapeutics, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ARTH
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	150769042	shares
CY2017Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2634604	USD
CY2016Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150769042	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	136657075	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150769042	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136657075	shares
	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	6068686	USD
	us-gaap	Stock Issued1 StockIssued1	106666	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	arth	Financing Cost On Issuance Of Common Stock And Warrants FinancingCostOnIssuanceOfCommonStockAndWarrants	93687	USD
	arth	Financing Cost On Issuance Of Common Stock And Warrants FinancingCostOnIssuanceOfCommonStockAndWarrants	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2996110	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Derivative Liabilities</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3925	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8218	USD
CY2017Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	22100	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	5500	USD
CY2017Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2996110	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12379210	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14504210	shares
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	228000	USD
	us-gaap	Interest Paid InterestPaid	361268	USD
	us-gaap	Interest Paid InterestPaid	0	USD

Files In Submission

Name	View Source	Status
0001144204-17-023801-index-headers.html	Edgar Link	pending
0001144204-17-023801-index.html	Edgar Link	pending
0001144204-17-023801.txt	Edgar Link	pending
0001144204-17-023801-xbrl.zip	Edgar Link	pending
arth-20170331.xml	Edgar Link	completed
arth-20170331.xsd	Edgar Link	pending
arth-20170331_cal.xml	Edgar Link	unprocessable
arth-20170331_def.xml	Edgar Link	unprocessable
arth-20170331_lab.xml	Edgar Link	unprocessable
arth-20170331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v464843_10q.htm	Edgar Link	pending
v464843_ex31-1.htm	Edgar Link	pending
v464843_ex31-2.htm	Edgar Link	pending
v464843_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2017 Q2 Form 10-Q Financial Statement

#000114420417023801 Filed on May 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2017 Q2 Form 10-Q Financial Statement

#000114420417023801 Filed on May 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth